Investor Newsletter

Issue 02 2017

MicroPort

Firehawk® Receives Regulatory Approval in South Korea

On January 24, Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®"), in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®"), received the regulatory approval from the Ministry of Food and Drug Safety ("MFDS") of South Korea.

The drug-eluting stent ("DES") is classified as the Type IV high-risk product, which is the priority of the MFDS' oversight and watch during the procedure of pre-market technical approval and post-launch supervision. For the pre-market approval procedure of DES, MFDS has two professional inspector teams to assess the safety and efficacy of the drug and the device/stent respectively. MicroPort® provided a large amount of testing data of Firehawk®, such as its pre-clinical data, clinical data, and documents of production technology control, to prove Firehawk®'s safety and efficacy and to show it complies with relevant regulations of South Korea, and therefore eventually obtained the approval from the MFDS and received the registration certificate. In October 2016, Firehawk® was granted the Korea Good Manufacturing Practice ("KGMP") certificate from the MFDS, which fully demonstrated that both of MicroPort®'s product quality and its quality management system comply with South Korea's regulations.

The revolutionary third-generation DES Firehawk® is the result of eight years of research and development of MicroPort® and it is the world's first and only target eluting stent ("TES"). As the world's lowest drug dosage stent, Firehawk® combines the merits of the bare metal stent and DES. It adopts unique in-groove abluminal coating design and target-eluting technique, which allow Firehawk® to achieve the same clinical efficacy with significantly low drug loading, benefiting vascular early healing.

In 2014, MicroPort®'s JIVE PTCA Balloon Catheter received the registration certificate in South Korea. Thus, Firehawk®'s regulatory approval will diversify MicroPort®'s product offerings in the South Korea market, paving the way for the company to further expand the local market.

Firehawk® Receives Regulatory Approval in Mexico

On January 18, Firehawk® received the regulatory approval from the health authority of the Mexican government - the Federal Commission for the Protection against Sanitary Risk (in Spanish, Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS). It is another registration certificate Firehawk® received in the South America markets following those in Peru, Brazil and Argentina.

Before Firehawk®'s regulatory approval in Mexico, another product of MicroPort® - FOXTROT™ PRO Balloon Dilation Catheter had gained the registration certificate from the COFEPRIS. With them, MicroPort® will provide better and more comprehensive medical solutions for South American patients by offering stent and balloon products used in the PCI in the Mexico market, which will also lay a solid foundation for the company to further expand the local market.

MicroPort

First Implantation of Firehawk® in India Completed

On February 15, a case using MicroPort® in-house developed Firehawk® was successfully completed in H. J. Doshi Ghatkopar Hindu Sabha Hospital based in Mumbai, India, marking the first clinical use of Firehawk® in India and a milestone in MicroPort®'s market development in the country.

India has the third largest amount of PCI cases in the world, and the market has been experiencing rapid development in recent years. In the future, MicroPort® will further expand the India market to provide ideal medical solutions for local patients suffering from cardiovascular diseases.

MicroPort

MicroPort® Attends CADECI and Completes First Firehawk® Implantation in Mexico

On February 24, a case using Firehawk® was successfully completed in a local hospital Jardines Hospital de Especialidades in Guadalajara of Mexico during the Mexico International Cardiology Annual Meeting (El Congreso Anual de Cardiología Internacional, CADECI). It is the first implantation of Firehawk® in Mexico following the regulatory approval from the health authority of the Mexican government - the Federal Commission for the Protection against Sanitary Risk (in Spanish, Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS) on January 18. The case was live broadcasted in the CADECI.

"We are very pleased that our star product Firehawk® is highly recognized in Mexico which is an important market in South America," said Dr. Linda Lin, First Vice President of MicroPort® International Business. "In the future, we hope to bring in more high-quality and high-end medical devices to Mexico to benefit local patients."



MicroPort

FOXTROT® NC PTCA Balloon Catheter Gains Regulatory Approval in Mexico

On January 16, FOXTROT® NC PTCA Balloon Catheter (“FOXTROT® NC”), in-house developed by MicroPort®, received the regulatory approval from the health authority of the Mexican government - the Federal Commission for the Protection against Sanitary Risk (in Spanish, Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS). In previous years, FOXTROT® NC had gained the CE mark, and received approvals from Japan's Ministry of Health Labour and Welfare ("MHLW"), US Food and Drug Administration (“FDA”) and China Food and Drug Administration (“CFDA”), and it was launched in the Philippines, Thailand and Brazil.

FOXTROT® NC is a non-compliant rapid exchange PTCA balloon dilatation catheter. The device features high burst pressure, low compliance and small balloon profile, which lead to its excellent pushability, trackability and crossability. FOXTROT® NC is indicated for the balloon catheter dilatation of the stenotic portion of a coronary artery, for the purpose of facilitating the implantation of balloon expandable stents, preventing the edge effects, protecting healthy tissues, as well as improving myocardial perfusion.

Aside from FOXTROT® NC, MicroPort®’s FOXTROT® PRO Balloon Dilatation Catheter and Firehawk® also obtained approval from the COFEPRIS. Dr. Linda Lin, First Vice President of MicroPort® International Business, said: “By offering stent and balloon products used in the PCI in the Mexico market, MicroPort® is on the way to provide more comprehensive medical solutions for South American patients.”

MicroPort

FireMagic™ Cardiac RF Ablation Catheter and EasyFinder™ Fixed Curve Diagnostic Catheter Gain MFDS Approval

On February 13, MicroPort® announced that its products FireMagic™ Cardiac RF Ablation Catheter and EasyFinder™ Fixed Curve Diagnostic Catheter received the regulatory approval from the MFDS of South Korea. The two products are both in-house developed by MicroPort®'s subsidiary Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP"). At the same time, MicroPort® EP passed the system audit of MFDS and obtained the certificate of Korea Good Manufacturing Practice ("KGMP"), valid for three years.

FireMagic™ Cardiac RF Ablation Catheter and EasyFinder™ Fixed Curve Diagnostic Catheter are designed for the diagnosis and treatment of arrhythmia. FireMagic™ Cardiac RF Ablation Catheter is a flexible, insulated catheter with a deflectable curve tip. It is composed of medical grade thermoplastic elastic polymer and a number of platinum electrodes. All of its electrodes can be used for cardiac electrophysiology mapping and stimulation, but only the tip electrode has the function of ablation. The FireMagic™ Catheter offers six types of curve shapes to permit accurate positioning in different areas of ventricle. EasyFinder™ Fixed Curve Diagnostic Catheter is consisted of a high-torque shaft and platinum electrodes. The electrodes are used for cardiac electrophysiology mapping and programmed stimulation. Its high-torque shaft allows the plane of the curved tip to be adjusted by manual rotation to facilitate accurate positioning of the catheter tip at the desired site.



MicroPort

MicroPort® Receives CFDA Approval for APOLLO Intracranial Stent System in Large Sizes

On January 23, MicroPort® received approval from CFDA for APOLLO Intracranial Stent System ("APOLLO") in large sizes, developed by its subsidiary MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech"). The newly approved large sizes have the same indications as that of the original sizes, consisting of a stent and a delivery system for treating intracranial artery stenosis by improving blood supplies in cerebral arteries.

APOLLO was first approved by CFDA in 2004. It was China's first intracranial stent for the treatment of ischemic cerebrovascular disease. It was awarded the second prize of Shanghai Scientific Progress Award in 2009, named Shanghai Key New Product in 2010, and then listed in the National Key New Product Scheme in 2011. The newly approved product includes 12 large sizes, which further expanded APOLLO's usage in treating 4.5mm and 5.0mm cerebral vessels, meeting the unmet clinical needs.

MicroPort® Attends AsiaPCR 2017

From January 19 to January 21, MicroPort® attended AsiaPCR 2017 held in Singapore. During the premier cardiovascular course in Asia that gathered renowned cardiovascular professionals from Asian countries including Singapore, China, Japan, South Korea, Malaysia and Thailand, MicroPort® displayed its new-generation drug-eluting stent Firehawk®, the upgraded balloon dilatation catheter Firefighter™ PTCA Balloon Dilatation Catheter ("Firefighter™") and some PCI accessories in its booth, which attracted many attendees to inquire for product information.

As the brand image of MicroPort® is gaining higher recognition among Indian physicians, several Indian professionals were attracted to visit MicroPort® booth. MicroPort® staff also received experts from Pakistan, Malaysia, the Philippines, Thailand and European countries, which will further enhance the mutual communications between MicroPort® and the international cardiovascular interventional specialists, paving the way for its international business development.

MicroPort® Holds Two Coronary Artery CTO Symposiums in Malaysia

On February 5 and February 17, MicroPort® held two coronary artery chronic total occlusion ("CTO") symposiums in Malaysia, during which several experts presented live cases to show the excellent performance of Firehawk®.

The two symposiums allowed attended physicians to get hands-on experience in Firehawk®, FOXTROT® PRO, and FOXTROT® NC, which will largely enhance their understanding and confidence in MicroPort® products.

"In 2017, MicroPort® will continue to work with Malaysian distributors to organize a series of symposiums regarding the application of Firehawk® and other MicroPort® products in treating complex coronary artery lesions to strengthen the communication between physicians of China and Malaysia, and at the same time we will carry out relevant clinical studies in Malaysia to provide more high-quality medical solutions for patients with coronary artery diseases by evidence-based medicine," said Dr. Linda Lin, First Vice President of MicroPort® International Business.

Firehawk® Displayed in 2017 Pakistan Live

From February 16 to February 18, MicroPort® attended the 2017 Pakistan Live in Karachi of Pakistan. The congress attracted around 1,000 professionals and physicians to participate, to improve their understanding in cardiovascular diseases by academic exchange and live cases, and share the latest advancement of cardiovascular interventional treatment. MicroPort® was present with a booth and broadcasted a live case of Firehawk®.

On February 17, Professor Rosli Bin Mohd Ali of Malaysia-based IJN National Heart Institute and Dr. Tariq Ashraf, an associate professor of National Institute of Cardiovascular Diseases in Pakistan, presented a live case of Firehawk®, and achieved successful outcome which was well recognized by experts in attendance. The two physicians spoke highly of the excellent visibility and trackability of Firehawk® and noted the device offers precise positioning and is easy to reach the lesion.

MicroPort® OrthoRecon Attends 2nd National Academic Conference in Enhanced Recovery After Arthroplasty

On February 18, Suzhou MicroPort OrthoRecon Co., Ltd. ("MicroPort® OrthoRecon") attended the 2nd National Academic Conference in Enhanced Recovery After Arthroplasty and Chinese Research Hospital Association on Founding Conference in Joint Surgery in Chengdu, Sichuan Province, which gathered around 1,000 surgeons from 28 provinces. MicroPort® OrthoRecon was present with a booth, and introduced the standard operation method and key technical points of SuperPath™ Micro-posterior Total Hip Arthroplasty ("SuperPath™").

MicroPort® OrthoRecon booth attracted a lot of surgeons who are interested in SuperPath™ to inquire for more product information. Among them, several surgeons expressed a willingness to learn more about SuperPath™ technique and perform SuperPath™ procedures in the future. By attending this conference, MicroPort® OrthoRecon increased the awareness of SuperPath™ and the "Full Function, Faster" concept, paving the way to further promote SuperPath™ in Western and Central China.

MicroPort

MicroPort® EP Attends the 9th VAS-CHINA

From February 17 to February 19, MicroPort® EP attended the 9th Ventricular Arrhythmia Symposium ("VAS-CHINA") in Nanjing, Jiangsu Province. Domestic and International experts were invited for academic exchange on hot topics of the ventricular arrhythmias field. During the congress, MicroPort® EP hosted a satellite meeting "Columbus™: Navigation for the Heart," which was well received by experts in attendance.

"It is Columbus™'s debut in a national-level arrhythmia conference after its launch in China in 2016, and it is expected that the satellite meeting would have helped increase its awareness in China," said Dr. Yiyong Sun. "Columbus™'s stability and safety have been highly recognized by many domestic and international electrophysiology professionals. We believe the product will bring benefit to an increasingly more arrhythmia patients."

MicroPort

Three Products of MicroPort® Included in 2016 Shanghai Innovative Product Recommendation List

Three products in-house developed by MicroPort® - Firehawk®, Columbus™ and WILLIS® Intracranial Stent Graft System ("WILLIS®") – were included in the Category of High-performance Medical Device of the 2016 Shanghai Innovative Product Recommendation List ("Recommendation List") according to an announcement recently released by Shanghai Municipal Commission of Economy and Informatization, Science and Technology Commission of Shanghai Municipality and Shanghai Zhangjiang High-tech Industrial Development Zone Management Committee.

The Recommendation List is designed to facilitate the implantation of Shanghai government's strategies to build a technological innovation center in the city, to promote the industry upgrading, companies' innovation and the commercialization of innovative products, as well as to cultivate new technologies, new businesses, new models and new industries. The Recommendation List is expected to provide references to decision makers of government purchasing, enterprise purchasing, funding allocation and investment and financing institutions.

The three products are innovations of many years' in-house research and development of MicroPort® and its subsidiaries. As they have been counted in the Recommendation List, it once again demonstrated MicroPort®'s sustainable innovation abilities.







MicroPort® Attends MD&M WEST 2017

From February 7 to February 9, MicroPort® attended the 2017 Medical Design & Manufacturing West ("MD&M WEST") held in Anaheim, California to display its products and OEM/ODM samples.

MD&M WEST is the world's largest annual expo of medical device and medical device design software, which has been held for 32 years. This year, the medtech event gathered more than 2,000 exhibitors and 20,000 attendees. During the expo, MicroPort® staff received over 150 visitors, most of whom showed great interest in our cardiovascular and orthopedic products. The visitors highly recognized MicroPort®'s diversified development strategy as well as its achievements in various business segments, and they were impressed by the products and the production capacities of MicroPort®'s two production centers through materials on display in its booth. During the expo, MicroPort® also researched several leading-edge R&D projects, to seek for opportunities for cooperation in R&D innovation.

Investor Newsletter

Issue 02 2017

MicroPort

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & Senior Director of External Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com